# FDA Approves 'New' Sunscreen Ingredient Used in Europe and Asia for Years
The FDA has approved bemotrizinol, a broad-spectrum sunscreen ingredient that has protected families across Europe and Asia for nearly two decades. This approval expands the limited options available to American parents seeking effective sun protection for their children and themselves.
Bemotrizinol blocks both UVA and UVB rays. European and Asian manufacturers have used this ingredient safely since the early 2000s, building a track record across millions of users. The FDA's approval process required submission of safety data that regulatory agencies abroad had already evaluated.
American sunscreen shelves have relied on a narrow set of active ingredients. Oxybenzone and octinoxate have faced scrutiny over potential hormone-disrupting effects. Mineral options like zinc oxide and titanium dioxide work well but can leave visible white casts on skin, which discourages consistent use, especially in children. Chemical sunscreens absorb into skin more easily, which some parents prefer, but fewer options mean fewer formulations.
Bemotrizinol fills this gap. It offers a chemical alternative with a different mechanism than the ingredients already approved in the United States. Parents who struggled with existing formulations now have another choice.
The timing matters. Dermatologists continue urging families to use sunscreen daily. The American Academy of Pediatrics recommends broad-spectrum SPF 30 or higher for children over six months old. Real-world compliance remains a challenge. When sunscreen feels greasy, leaves residue, or irritates sensitive skin, families skip application or reapplication. A new ingredient that formulates differently could shift these behaviors.
Bemotrizinol won't replace existing sunscreens for families finding success with current products. But for parents whose children refuse sunscreen due to texture or appearance,